Skip to content

🇪🇺 Fast delivery (3–5 working days) with GLS ✅ Bank transfer in advance 📦 Free shipping from €50

Peptides for weight loss

Retatrutide
Tirzepatide
Semaglutide
Cagrilintide

Peptides for weight loss

Peptides for weight loss: GLP-1, GIP and glucagon agonists and amylin analogues

The Peptology category “Peptides for weight loss” brings together molecules that act on appetite regulation and energy metabolism through three different mechanisms: the incretin pathway (GLP-1 and GIP), the glucagon pathway and the amylin pathway. The difference between the products is not their “strength” but how many receptors they activate — and which ones.

All products ship with GLS in 3–5 working days — lyophilised, with confirmed purity above 99% (HPLC/MS) and an independent laboratory certificate (CoA) for every batch.

The three mechanisms of the category

THE INCRETIN PATHWAY

GLP-1 is the hormone the gut releases after a meal. Its agonists slow gastric emptying and act on the hypothalamic satiety centres. GIP is the second incretin, with a role in lipid handling.

THE GLUCAGON PATHWAY

The glucagon receptor works on the other side of the energy balance — not on intake but on expenditure. It is the only pathway in the category that raises energy expenditure rather than only lowering appetite.

THE AMYLIN PATHWAY

Amylin is secreted alongside insulin by the beta cells and acts through its own receptors, entirely separate from the incretin receptors. That is why it combines logically with a GLP-1 agonist.

Best-selling products in the category

Three products cover most of the scenarios being studied — one for each level of mechanistic complexity.

BESTSELLER

RETATRUTIDE

The triple agonist. GLP-1, GIP and glucagon in a single molecule. Published phase-2 data report an average body-weight reduction of about 24% and a drop in liver fat of over 80%, with a half-life of roughly 6 days.

TIRZEPATIDE

The dual GIP/GLP-1 agonist. The first molecule of the class to activate two incretin receptors at once. Average weight reduction of about 22.5% in published studies — the balance between a strong effect and a well-documented profile.

CS10 (CAGRILINTIDE + SEMAGLUTIDE)

Two independent pathways in one vial. 5 mg cagrilintide and 5 mg semaglutide — amylin plus incretin. The CS20 variant contains 10 + 10 mg in the same ratio.

Comparison: the three generations of incretin agonists

Semaglutide, tirzepatide and retatrutide are not variants of the same molecule but three levels of complexity. Each generation adds one more receptor pathway.

Feature Retatrutide Tirzepatide Semaglutide
Receptors activated GLP-1 + GIP + glucagon GLP-1 + GIP GLP-1
Weight reduction in studies ≈ 24% ≈ 22.5% ≈ 16%
Energy expenditure Directly increased Indirectly affected Indirectly affected
Liver fat Reduction over 80% Marked reduction Moderate reduction
Typical choice for The broadest metabolic model A strong effect with a known profile The GLP-1 reference model

≈ 24%

RETATRUTIDE, PHASE 2

≈ 22.5%

TIRZEPATIDE

≈ 16%

SEMAGLUTIDE

99%+

PURITY WITH CoA

Which peptide for which research model?

Combinations of products from the category

The rule is simple: you combine molecules that act on different receptors. Two molecules binding the same receptor do not add up — they compete.

AMYLIN + INCRETIN

Cagrilintide + semaglutide — two completely separate receptor systems. That is exactly the composition of CS10 and CS20.

READY-MADE OR SEPARATE

The same two molecules can also be used from separate vials when the model calls for a ratio other than 1:1, or for introducing one of them gradually.

+ SOLVENT

Every peptide needs a suitable reconstitution medium. See the Solutions for peptides category.

Conversely — semaglutide together with tirzepatide or retatrutide — adds no information: all three bind the GLP-1 receptor and compete for it. The same applies to CS10 together with separate semaglutide — the GLP-1 component is already in the vial.

Storage and safety rules

In lyophilised form the products are stable at controlled room temperature (20–25 °C), protected from direct light and moisture. After reconstitution every peptide in this category is kept refrigerated.

Important notice: The products in this category are intended exclusively for laboratory research and scientific in-vitro analysis. They are not medicines, not approved preparations and not suitable for use in humans or animals. The mechanisms described come from the published scientific literature and constitute neither a promise of effect, nor a recommendation for use, nor a claim about the action of the research-grade products offered. A general comparison of the whole class is given in GLP-1 agonists: the new benchmarks.